Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corcept Therapeutics 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 USA

P: 650-327-3270 F: 650-327-3218

Description:

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

Key Statistics

Overview:

Market Capitalization, $K 2,460,879
Enterprise Value, $K 2,237,339
Shares Outstanding, K 107,650
Annual Sales, $ 365,980 K
Annual Net Income, $ 112,510 K
Last Quarter Sales, $ 101,730 K
Last Quarter Net Income, $ 31,400 K
60-Month Beta 0.59
% of Insider Shareholders 18.60%
% of Institutional Shareholders 80.08%
Float, K 87,627
% Float 81.40%
Short Volume Ratio 0.85

Growth:

1-Year Return 27.27%
3-Year Return 76.55%
5-Year Return 64.08%
5-Year Revenue Growth 350.05%
5-Year Earnings Growth 1,171.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.30 on 11/03/22
Next Earnings Date 02/21/23
Earnings Per Share ttm 1.00
EPS Growth vs. Prev Qtr 25.00%
EPS Growth vs. Prev Year 25.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CORT Ratios

Ratio
Price/Earnings ttm 22.99
Price/Earnings forward 25.26
Price/Earnings to Growth N/A
Return-on-Equity % 27.49%
Return-on-Assets % 24.31%
Profit Margin % 30.74
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 7.07
Price/Cash Flow 22.97
Price/Book 5.23
Book Value/Share 4.40
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar